Syntis Bio received a $33 million to advance its oral therapy platform for obesity, diabetes, and rare metabolic diseases. The company’s nutrient-blocking pill leverages transient polymer coatings and gut-stable enzyme therapies to provide a non-surgical treatment option that mimics the benefits of bariatric surgery while expanding therapeutic possibilities for rare metabolic disorders.
All entries for: Investment
July 1, 2025
Renasant Bio
Investment
Renasant Bio received $0.26 million to advance its small-molecule therapy platform targeting genetic kidney disorders, including autosomal dominant polycystic kidney disease (ADPKD), to develop the first disease-modifying oral treatments for patients.
Disease Area: Rare Diseases
July 1, 2025
Quiver Bioscience
Investment
Quiver Bioscience secured $0.91 million investment to enhance its CNS genetic medicine discovery platform and improve safety prediction for antisense oligonucleotide therapeutics. The company’s portfolio includes programs advancing precision treatments for both common and rare neurological disorders, including Dup15q syndrome, Fragile X syndrome, and KCNT1-related epilepsy.
Disease Area: Rare Diseases
June 1, 2025
Regatta Bio
Investment
Regatta Bio received an undisclosed investment to advance its portfolio of regulatory T cell (Treg) therapies designed to treat immune-mediated and rare disorders, including chronic graft-versus-host disease (cGvHD), solid organ rejection, autoimmune diseases, and inflammatory conditions.
Disease Area: Rare Diseases